Trastuzumab biosimilar - Pfizer

Drug Profile

Trastuzumab biosimilar - Pfizer

Alternative Names: PF-05280014; PF-5280014; Trastuzumab - Pfizer

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Breast cancer

Most Recent Events

  • 31 Oct 2017 EMA accepts MAA for trastuzumab biosimilar for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) for review in July 2017
  • 31 Oct 2017 US FDA sets April 2018 as a Biosimilar User Fee Act goal date for trastuzumab biosimilar BLA in Breast cancer
  • 31 Oct 2017 US FDA accepts BLA for trastuzumab biosimilar for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) for review in August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top